Pfizer Inc. [PFE.N]
Vigilo - Real Time Intelligence Report
Company Information
| Company Name | Ticker | As of Date | |
|---|---|---|---|
| Pfizer Inc. | PFE.N | 02-07-2024 | |
| Sector | Industry | ||
| Healthcare | Pharmaceuticals - Diversified | ||
| Country | |||
| USA | |||
Key Risk Metrics
| Period | ST | LT |
|---|---|---|
| Cumulative Score | 0.2 | 1.3 |
| Credit Risk Rating | B | B |
Heat Map
Business Description
Pfizer Inc. operates as a pharmaceutical company. It offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Company level
Our 0-3 months cumulative score on Pfizer Inc. [PFE.N] is 0.2 represents strongly positive impact of the recent events. ST rating B represents a moderate level of credit risk. In our opinion there is a moderate probability that the company will not be able to meet its financial commitments if operating performance worsens and/or in the event of significant adverse changes in the economic environment.
Pfizer Inc. has agreed to settle more than 10,000 cases accusing it of hiding the cancer risks of its Zantac heartburn drug, according to people familiar with the deal, the biggest of the litigation.
Pfizer Inc. paused a study of an experimental gene therapy for muscular dystrophy after a child who received it died suddenly. Pfizer has paused administering the same gene therapy in a separate, final-stage study while it investigates the boy's death.
Pfizer has agreed to pay $93 million to settle antitrust claims by wholesale drug distributors that accused it of conspiring with India's Ranbaxy Laboratories to delay sales of less expensive, generic versions of the cholesterol drug Lipitor.
Macro Level
The US central bank again said it would keep interest rates unchanged, noting a "lack of further progress" toward lowering inflation. The decision left the Federal Reserve's key rate hovering at the highest level in more than two decades, in the range of 5.25%-5.5%, where it has stood since last July.
Employment growth in the United States remains plentiful as employers added 303,000 jobs in March and the unemployment rate fell to 3.8 per cent, according to data released by the Bureau of Labor Statistics on Friday.
Industry Level
The country's drugs and pharmaceuticals exports increased 9.67 per cent year-on-year to $27.9 billion in 2023- 24, even as the total exports dipped by 3 per cent in the last fiscal. According to the commerce ministry data, pharma exports in March grew by 12.73 per cent to $2.8 billion.